$ACT

ENACT REPORTS SECOND QUARTER 2026 RESULTS; ANNOUNCES $0.24 QUARTERLY DIVIDEND

Enact Holdings, Inc. (ACT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ENACT REPORTS SECOND QUARTER 2026 RESULTS; ANNOUNCES $0.24 QUARTERLY DIVIDEND _______________________________________ GAAP Net Income of $175 million, or $1.25 per diluted share Adjusted Operating Income of $177 million, or $1.26 per diluted share Return on Equity of

Original reporting
Published Aug 5, 2026, 8:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 5, 2026, 8:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ACT
Bullish
high confidence
Mentioned
$ACT
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ACTBullishMed
01

Why it matters

Traders can update models around ACT’s earnings power, capital adequacy (PMIERs sufficiency), and shareholder yield (dividend plus buybacks) ahead of the scheduled Aug 6 call.

02

Market read

The filing combines a quarterly earnings print with a raised 2026 capital return range and a declared dividend, which are direct inputs to near-term valuation and positioning.

03

What to watch

The release notes one-time reorganization costs affecting operating expenses and reserve-release dynamics; investors may scrutinize whether profitability is sustainable into 2H26.

Relevance 7/10Novelty 8/10Timing: after-hours filing today, before the Aug 6 conference call

Background

This is an SEC 8-K with Enact’s 2Q26 results (Item 2.02) and an earnings release exhibit, including capital return updates and a dividend declaration.

Company-level read

Ticker impact

$ACTBullishHigh confidence
Context

Enact reported 2Q26 results and raised full-year capital return guidance to $550 million to $600 million, plus declared a $0.24 dividend.

Expected impact

Likely supportive for the stock, with upside bias if investors view the raised capital return range and ROE metrics as durable.

Evidence & confidence

The filing discloses multiple concrete, investor-relevant datapoints: GAAP and adjusted earnings, ROE, PMIERs sufficiency, repurchases, raised 2026 capital return guidance, and a declared dividend with a specific payable date.

Market effects

Reinforces capital-return and credit-resilience narrative for mortgage insurance providers, potentially supporting sector sentiment.

Limited, company-specific disclosure with no stated regional macro linkage.

Low, US-listed issuer filing with no cross-border transaction details.

Counterpoint

Persistency is down year over year (80% vs 82%), which could temper enthusiasm despite higher capital return guidance.

Key entities

  • Enact Holdings, Inc.

    Nasdaq-listed mortgage insurance provider reporting 2Q26 financial results and capital return guidance.

  • EMICO

    Mentioned as completing a $150 million dividend in 2Q26 to support Enact’s capital return capacity.

Related articles

$ACTMed

JPMorgan downgrades Enact Holdings stock rating on valuation

JPMorgan downgraded Enact Holdings (ACT) to Underweight, lowering its price target to $44.00. The stock trades at $45.97, above the target and fair value estimates, suggesting overvaluation. JPMorgan cited premium valuation and mixed effects from higher interest rates. Enact reported Q2 2026 earnings beating estimates, with $1.26 EPS and $317.3M revenue. BTIG initiated coverage with a Neutral rating, noting expected ROE declines.

$ACTMedAI 8/10

Enact (ACT) Q2 2026 Earnings Call Transcript

Enact (ACT) reported Q2 2026 adjusted operating income of $177 million, or $1.26 per diluted share, up from $174 million, or $1.15, in Q2 2025. New insurance written rose 15% to $15 billion. FY2026 capital return guidance was raised to $550 million to $600 million. Management cited $274 billion insurance in force and 161% PMIERs sufficiency.